Choose a consistent time window that works for your schedule and medication instructions
Additionally, some patients report improved quality of life related to better glucose control, weight loss, and the convenience of once-weekly dosing options
& Vasseur, J
Confusion arose, however, because the peptide was also being offered without DAC
Oral GLP-1s for obesity saw a recent setback when in April (April 2025), Pfizer announced that it was discontinuing development of danuglipron, an oral GLP-1 receptor agonist, which was being investigated for chronic weight management, due to potential liver toxicity
Some may experience mild nausea as the body adjusts, this typically subsides